By Partha Ghosh, MD, Siemens Healthineers, Hoffman Estates, Illinois, USA
Clinical impact of absolute SPECT/CT quantification in theranostics and dosimetry
Major advances in SPECT/CT technology have enabled absolute quantification to be accurate and reproducible. Download the white paper and explore the clinical impact of SPECT/CT quantification in theranostics and dosimetry.
By Vijay Shah, Ph.D., Siemens Healthineers
By Rachid Fahmi, PhD and Guenther Platsch, MD, Siemens Healthineers
By Carl von Gall, MD, Vijay Shah, PhD, and Ludovic Sibille, MSc, Siemens Healthineers
By Bruce Spottiswoode, Ph.D.; Damita Thomas, M.D.
By A. Hans Vija, PhD; Carl von Gall, MD; and Partha Ghosh, MD, Siemens Healthineers
The introduction of xSPECT Quant™ for absolute quantification of 177Lu, 111In, and 123I is a major step toward implementation and expansion of standardized evidence-based medicine in the realm of radionuclide imaging. Download the white paper to learn more about Siemens Healthineers’ xSPECT Quant technology.
This white paper discusses the impact of PET/CT in staging and re-staging patients with inflammatory, locally advanced and metastatic breast cancer. Treatment guidelines and reimbursement are included.
This white paper reviews guidelines and studies to show how PET/CT is a powerful modality to assess cervical cancer, in particular in tumors of stage IB and beyond and can depict, for example, lymphatic involvement and distant metastases.
This white paper addresses the needs of the clinician to ensure optimal patient management as well as appropriate use of PET/CT imaging.
This white paper explores the role of PET/CT in imaging high-risk patients (such as those with an elevated PSA level or Gleason score) for skeletal metastases. It reviews PET's role on therapy decisions during initial diagnosis and therapy monitoring.